(NASDAQ: ALKS) Alkermes's forecast annual revenue growth rate of 8.42% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.23%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Alkermes's revenue in 2026 is $1,667,652,000.On average, 21 Wall Street analysts forecast ALKS's revenue for 2026 to be $311,871,922,648, with the lowest ALKS revenue forecast at $294,592,305,632, and the highest ALKS revenue forecast at $326,970,617,128. On average, 21 Wall Street analysts forecast ALKS's revenue for 2027 to be $330,829,172,384, with the lowest ALKS revenue forecast at $289,559,407,472, and the highest ALKS revenue forecast at $388,036,448,136.
In 2028, ALKS is forecast to generate $358,174,585,720 in revenue, with the lowest revenue forecast at $308,684,420,480 and the highest revenue forecast at $474,434,533,216.